Donepezil / memantine Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Oct 31, 2022.
Donepezil / memantine is also known as: Namzaric
Donepezil / memantine Pregnancy Warnings
Animal studies with memantine have revealed evidence of slight maternal toxicity, decreased offspring weights, and increased incidence of non-ossified cervical vertebrae at an oral dose 6 times the maximum recommended human dose (MRHD). Animal studies with donepezil showed an increase in stillbirths and reduced offspring survival at oral doses up to 7 times the MRHD. Other doses of memantine and donepezil examined in animal studies, including doses up to 21 and 15 times the MRHD, did not show any teratogenic effects. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Benefit should outweigh risk
US FDA pregnancy category: C
Donepezil / memantine Breastfeeding Warnings
Caution is recommended; safety has not been established
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Namzaric (donepezil-memantine)." Forest Pharmaceuticals (2015):
References for breastfeeding information
- "Product Information. Namzaric (donepezil-memantine)." Forest Pharmaceuticals (2015):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
